Vagus nerve modulates acute-on-chronic liver failure progression via CXCL9.
10.1097/CM9.0000000000003104
- Author:
Li WU
1
;
Jie LI
1
;
Ju ZOU
1
;
Daolin TANG
2
;
Ruochan CHEN
1
Author Information
1. Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
2. Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
- Publication Type:Journal Article
- Keywords:
ACLF;
Acute-on-chronic liver failure;
CXCL9;
Neuroimmune communication;
Vagus nerve
- MeSH:
Animals;
Mice;
Chemokine CXCL9/metabolism*;
Vagus Nerve/physiology*;
Acute-On-Chronic Liver Failure/metabolism*;
Humans;
Male;
Mice, Inbred C57BL;
Proteomics;
Flow Cytometry;
Receptors, CXCR3/metabolism*
- From:
Chinese Medical Journal
2025;138(9):1103-1115
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Hepatic inflammatory cell accumulation and the subsequent systematic inflammation drive acute-on-chronic liver failure (ACLF) development. Previous studies showed that the vagus nerve exerts anti-inflammatory activity in many inflammatory diseases. Here, we aimed to identify the key molecule mediating the inflammatory process in ACLF and reveal the neuroimmune communication arising from the vagus nerve and immunological disorders of ACLF.
METHODS:Proteomic analysis was performed and validated in ACLF model mice or patients, and intervention animal experiments were conducted using neutralizing antibodies. PNU-282987 (acetylcholine receptor agonist) and vagotomy were applied for perturbing vagus nerve activity. Single-cell RNA sequencing (scRNA-seq), flow cytometry, immunohistochemical and immunofluorescence staining, and clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) technology were used for in vivo or in vitro mechanistic studies.
RESULTS:The unbiased proteomics identified C-X-C motif chemokine ligand 9 (CXCL9) as the greatest differential protein in the livers of mice with ACLF and its relation to the systematic inflammation and mortality were confirmed in patients with ACLF. Interventions on CXCL9 and its receptor C-X-C chemokine receptor 3 (CXCR3) improved liver injury and decreased mortality of ACLF mice, which were related to the suppressing of hepatic immune cells' accumulation and activation. Vagus nerve stimulation attenuated while vagotomy aggravated the expression of CXCL9 and the severity of ACLF. Blocking CXCL9 and CXCR3 ameliorated liver inflammation and increased ACLF-associated mortality in ACLF mice with vagotomy. scRNA-seq revealed that hepatic macrophages served as the major source of CXCL9 in ACLF and were validated by immunofluorescence staining and flow cytometry analysis. Notably, the expression of CXCL9 in macrophages was modulated by vagus nerve-mediated cholinergic signaling.
CONCLUSIONS:Our novel findings highlighted that the neuroimmune communication of the vagus nerve-macrophage-CXCL9 axis contributed to ACLF development. These results provided evidence for neuromodulation as a promising approach for preventing and treating ACLF.
